Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

(1997): Gilchrest BA, JAmAcadDermatol36, S27
(1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ (29%)
([O])
(1992): Olsen EA+, JAmAcadDermatol26, 215
(1991): Weinstein GD+, Arch Dermatol 127, 659
(1989): Goldfarb MT+, JAmAcadDermatol21, 645
(1989): Leyden JJ+, JAmAcadDermatol21, 638
Erythema (1–49%) [O][T]
(2001): Vandana B+, AAPS PharmSciTech 2(3), Technical Note 4
(2000): Kreusch+, Curr Med Res & Opinion 16(1), 1
(1998): Ellis CN+, Br J Dermatol 139 Suppl 52, 41
(1998): Webster GF, JAmAcadDermatol39(2), S38
(1997): Drug Information Handbook Fifth Ed (American
Pharaceutical Association, Hudson, OH)
(1997): Cunliffe WJ+, JAmAcadDermatol36(6), S126
(1997): Gilchrest BA, JAmAcadDermatol36(3), S27
(1996): Shalita A+, JAmAcadDermatol34(3), 482
(1996): Shroot B, Presented at Dermatology Update ‘95,
Montreal, Canada
(1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ
(1995): Hall R, Inpharma December, 13
(1992): Olsen EA+, JAmAcadDermatol26(2), 215
(1991): Weinstein GD+, Arch Dermatol 127, 659
(1989): Goldfarb MT+, JAmAcadDermatol21, 645
(1989): Leyden JJ+, JAmAcadDermatol21, 638
(1988): Cohen BA+, Pediatric Dermatology 1. New York:
Churchill Livingstone, 663
Erythema nodosum
(2005): Taguchi A+, Rinsho Ketsueki 46(3), 202
(2004): Kuo MC+, Ann Hematol 83(6), 376 (4 cases)
(1993): Hakimian D+, Leukemia 7(5), 758
Exfoliative dermatitis (8.3%) [O]
(1998): Webster GF, JAmAcadDermatol39, S38
(1997): Cunliffe WJ+, JAmAcadDermatol36, S126
(1988): Huang ME+, Blood 72(2), 567
Facial edema (1–10%) [O]
(1997): Drug Information Handbook Fifth Ed. American
Pharmaceutical Association, Hudson, OH
(1995): Package insert Hoffman-LaRoche, Inc., Nutley NJ
Flaking (23%) [O]
Hyperkeratosis (78%) [O]
(1991): Chen ZX+, Blood 78, 1413
Hypomelanosis (5%)
(1998): Webster GF, JAmAcadDermatol39, S38
(1997): Cunliffe WJ+, JAmAcadDermatol36, S126
Irritation (5%)
(2003): Greenspan A+, Cutis 72(1), 76
(2001): Vandana B+, AAPS PharmSciTech 2(3), Technical Note 4
(1998): Cohen BA+, Pediatric Dermatology 1, New York:
Churchill Livingstone, 663
(1997): Clucas A+, JAmAcadDermatol36, S116
(1996): Shalita A+, JAmAcadDermatol34(3), 482
Pallor (1–10%) [O]
(1997): Drug Information Handbook Fifth Ed. American
Pharmaceutical Association, Hudson, OH
(1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ
Palmar–plantar desquamation (1–10%) [O]
(1997): Drug Information Handbook Fifth Ed. American
Pharmaceutical Association, Hudson, OH
(1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ
Photosensitivity (10%) [O][T]
(1998): Webster GF, JAmAcadDermatol39, S38
(1997): Drug Information Handbook Fifth Ed. American
Pharmaceutical Association, Hudson, OH
(1997): Cunliffe WJ+, JAmAcadDermatol36, S126
(1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ
Pigmentation (5%)
(1998): Webster GF, JAmAcadDermatol39, S38
(1997): Cunliffe WJ+, JAmAcadDermatol36, S126
TRETINOIN 553
Pruritus (10–40%) [O][T]
(2001): Vandana B+, AAPS PharmSciTech 2(3), Technical Note 4
(2000): Kreusch+, Curr Med Res & Opinion 16(1), 1
(1998): Ellis CN+, Br J Dermatol 139 Suppl 52, 41
(1998): Webster GF, JAmAcadDermatol39, S38
(1997): Drug Information Handbook Fifth Ed. American
Pharmaceutical Association, Hudson, OH
(1997): Cunliffe WJ+, JAmAcadDermatol36, S126
(1996): Shalita A+, JAmAcadDermatol34, 482
(1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ
(1995): Gillis JC+, Drugs 50(5), 897
(1988): Cohen BA+, Pediatric Dermatology 1, New
York:Churchill Livingstone, 663
Pyogenic granuloma
(2004): Teknetzis A+, J Eur Acad Dermatol Venereol 18(3), 337 (2
cases)
(1998): MacKenzie-Wood AR+, Australas J Dermatol 39(4), 248
Rash (sic) (54%) [O][T]
(1998): Webster GF, JAmAcadDermatol39, S38
(1997): Drug Information Handbook Fifth Ed American
Pharmaceutical Association, Hudson, OH
(1997): Cunliffe WJ+, JAmAcadDermatol36, S126
(1995): Package insert Hoffman-LaRoche, Inc.,Nutley, NJ
(1991): Warrell RP+, NEnglJMed324, 1385
Retinoic Acid–APL (RA-APL) syndrome*(25%) [O]
(2003): Paydas S+, Leuk Lymphoma 44(3), 547
(1997): Fenaux P+, NEnglJMed337, 1076
(1997): Sacchi S+, Haematologica 82(1), 106
(1997): Tallman MS+, NEnglJMed337, 1021
(1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ
(1995): Gillis JC+, Drugs 50, 897
(1992): Fenaux P+, Blood 80, 2176
Scaling (10–40%)
(2001): Vandana B+, AAPS PharmSciTech 2(3), Technical Note 4
(2000): Kreusch+, Curr Med Res & Opinion 16(1), 1
(1998): Ellis CN+, Br J Dermatol 139 Suppl 52, 41
(1997): Gilchrest BA, JAmAcadDermatol36, S27–36
(1996): Shalita A+, JAmAcadDermatol34, 482
(1996): Shroot B, Presented ar Dermatology Update ‘95 Montreal,
Canada
(1995): Hall R, Inpharma December, 13
(1992): Olsen EA+, JAmAcadDermatol26, 215
(1991): Weinstein GD+, Arch Dermatol 127, 659
(1989): Goldfarb MT+, JAmAcadDermatol21, 645
(1988): Cohen BA+, Pediatric Dermatology 1NewYork:
Chrurchill Livingstone, 663
Shivering (63%) [O]
(1997): Drug Information Handbook Fifth Ed. American
Pharmaceutical Association, Hudson, OH
(1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ
Stinging (1–26%)
(2001): Egan N+, Cutis 68(4 Suppl), 20
(1997): Gilchrest BA, JAmAcadDermatol36, S27
(1996): Shalita A+, JAmAcadDermatol34, 482
(1992): Olsen EA+, JAmAcadDermatol26, 215
(1991): Weinstein GD+, Arch Dermatol 127, 659
(1989): Goldfarb MT+, JAmAcadDermatol21, 645
(1989): Leyden JJ+, JAmAcadDermatol21, 638
Sunburn (1%)
(1996): Shalita A+, JAmAcadDermatol34, 482
Ulcerations (penile)
(2005): Mourad YA+, Int J Dermatol 44(1), 68 (scrotal)
(2005): Simzar S+, JDrugsDermatol4(2), 231 (scrotal)
(2004): Gettinger S+, J Clin Oncol 22(22), 4648 (scrotal)
(2004): Pavithran K+, Am J Hematol 75(4), 260 (scrotal)
(2004): Paydas S, Am J Hematol 77(2), 206 (scrotal)
(2003): Fukuno K+, Leuk Lymphoma 44(11), 2009 (scrotal)
(2000): Esser AC+, JAmAcadDermatol43(2 Pt 1), 316
(1995): Gillis JC+, Drugs 50, 897